{"title":"Case Report: Buprenorphine for Palliation in a Patient with End Stage Renal Disease.","authors":"Sing Ping Chow, Scott Donelenko, Chris Coppock","doi":"10.1080/15360288.2024.2435425","DOIUrl":null,"url":null,"abstract":"<p><p>End stage renal disease (ESRD) is known to be associated with pain, malaise and decreased quality of life. Pain management in the setting of dialysis is particularly challenging from a pharmacologic standpoint given altered pharmacokinetics of pain medications. Buprenorphine, a partial mu opioid receptor agonist, demonstrates superior safety profile compared to full mu opioid receptor agonists. In this case report, we demonstrated buprenorphine buccal film (Belbuca) as a safe and effective opioid treatment option for pain palliation in a dialysis dependent patient. Future studies may be warranted with larger sample size and longer follow up period to study the effect of buprenorphine in the setting of hemodialysis and non-dialysis dependent ESRD population.</p>","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-4"},"PeriodicalIF":0.9000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pain & Palliative Care Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15360288.2024.2435425","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
End stage renal disease (ESRD) is known to be associated with pain, malaise and decreased quality of life. Pain management in the setting of dialysis is particularly challenging from a pharmacologic standpoint given altered pharmacokinetics of pain medications. Buprenorphine, a partial mu opioid receptor agonist, demonstrates superior safety profile compared to full mu opioid receptor agonists. In this case report, we demonstrated buprenorphine buccal film (Belbuca) as a safe and effective opioid treatment option for pain palliation in a dialysis dependent patient. Future studies may be warranted with larger sample size and longer follow up period to study the effect of buprenorphine in the setting of hemodialysis and non-dialysis dependent ESRD population.